Pipeline specialized for Musculoskeletal Diseases


이뮤노포지㈜는 근골격계 희귀질환 신약 후보물질을 발굴하며, 다수의 신약 파이프라인을 보유하고 있습니다.

  • Home
  • >
  • Pipeline
  • >
  • Pipeline

주요 파이프라인 현황

Identification Indication Market 기초연구
PF1801 DMD Global
BMD Global
Polymyositis Global
Inclusion Body Myositis Global
Senile Sarcopenia Global
PF1802 ALS Global
PF1803 Degenerative Arthritis Global
KF1601 CML Domestic
  • Biological – A novel long acting GLP-1(glucagon-like peptide-1) receptor agonist
  • GLP-1 receptor activation may have a potential therapeutic application as a treatment for diseases that involve muscle atrophy and muscle wasting.
    (Ref: Hong et el., 2019)
  • Elastin-Like Polypeptide (ELP) half-life extension technology platform enables once weekly injection
  • Safety profile based on clinical data from phase 2b study in type 2 diabetes (20 weeks)
  • Drug re-positioning global development strategy :
    Targeting various indications involved in muscle atrophy including DMD, BMDand Polymyositis
  • Stage :
    IND submission for phase IIa in DMD

DMD (Duchenne Muscular Dystrophy)
BMD (Becker Muscular Dystrophy)

  • DMD and BMD are genetic disorders characterized by the progressive loss of muscle
  • Difficulty rising from a lying or sitting position
  • Large calf muscle, Walking on toes
  • BMD is a milder version of DMD
  • the mutated DMD gene fails to produce virtually any functional dystrophin
  • BMD genetic mutations make partially functional dystrophin
Standard Therapy
  • High dose glucocorticoids

Polymyositis (다발성 근염)

  • A rare, idiopathic, inflammatory myopathy
  • Symmetric proximal muscle weakness
  • In severe cases, causes dysphagia or dysphonia
  • Serious threat to the quality of daily life
  • Auto-immune responses in skeletal muscle
  • Lymphocyte infiltration in the muscle
Standard Therapy
  • High dose glucocorticoids
  • Glucocorticoid-induced toxicity

IBM (Inclusion body myositis, 봉입체 근염)

  • A complex disease with degenerative pathological mechanisms as well as autoimmune mediated by T lymphocytes
  • Progressive muscle weakness in distal finger flexor muscles and the quadriceps
  • Unlike other myositis, asymmetric and distal muscle weakness are likely to appear with slow disease progression
  • Inflammatory cells invade the muscle tissue and concentrate between the muscle fibers presenting multiple inclusion bodies that contain cellular material of dead tissue.
Standard Therapy
  • Immunosuppressant drugs
  • Corticosteroid doesn’t work for IBM.

Senile Sarcopenia (노인성 근감소증)

  • Senile sarcopenia is the loss of muscle mass due to the natural aging process
  • Loss of lean muscle mass and decreased muscle size
  • Reduced strength, functional decline and increased risk of falling
  • Senile sarcopenia is likely the result of multiple interacting factors such as changes in hormones, age-related muscle changes, nutrition, and lifestyle
Standard Therapy
  • Currently there are no medication to treat senile sarcopenia
BBB penetration and bio-availability enhanced first-in-classALS therapeutic candidate
BBB penetration and bio-availability enhanced first-in-classALS therapeutic candidate
BBB penetration and bio-availability enhanced first-in-classALS therapeutic candidate
  • Indication
    : ALS (Amyotrophic lateral sclerosis)
    (also known as Lou Gehrig's disease Or motor neurone disease)
  • ALS
    : ALS is a devastating neurodegenerative disease that results in progressive loss of motoneurons, motor weakness and death within 3-5 years after disease onset.
  • Class
    : Biologics, Dual ligand Fc fusion protein
  • Global market size expectation : USD 800 million in 2026
  • Status : in vivo PK
  • Next plan : in vivo Efficacy test
Indication: Degenerative arthritis
  • Class: First-in-class new biologic drug: dual function fusion protein
  • Most common degenerative joint disease with extreme pain from joint cartilage destruction or regression
  • Global market: $ 6 billion in 2019 → $ 9 billion in 2024 (CAGR: 8.1%)
  • Novel Disease-modifying osteoarthritis drug (DMOAD)
  • Status: Stable cell line development
New Chemical Entity
  • KF1601 is a rationally designed BCR-ALB inhibitor
    with activity against the common resistance mutation T315I
Developmental Strategy
  • Ponatinib is the first licensed BCR-ABL inhibitor with activity against T315I, but has significant side effects, including cardiac and vascular events
  • KF1601 has been developing to overcome the side effects of ponatinib
Developmental Stage
  • KF1601 is planned to enter non-clinical development in